黏膜-管腔界面蛋白质组学揭示儿童炎症性肠病相关结肠炎的生物标志物
研究对未治疗儿童诊断性结肠镜时采集升结肠和降结肠的黏膜-管腔界面抽吸液,用液相色谱质谱分析18例非IBD和42例IBD患者的蛋白质组,发现区分活动性IBD与非IBD及区分全结肠炎与非全结肠炎的蛋白质组合,并在粪便样本(n=24)中验证部分标志物。
要点
- 四蛋白组合区分活动性IBD与非IBD,升结肠灵敏度0.954、降结肠>0.999,两者特异度均>0.999。
- 另一四蛋白组合区分UC全结肠炎与非全结肠炎,灵敏度与特异度均>0.999。
- IBD粪便中过氧化氢酶(p<0.0001)和LTA4H(p=0.0002)较非IBD升高。
核心结论
- 研究识别出表达水平显著不同、有助于儿童UC准确诊断和疾病范围表征的蛋白质组合,MLI来源的标志物在粪便样本中呈现可迁移结果。
研究设计与样本
- 在诊断性结肠镜期间从初治儿童采集升结肠和降结肠的黏膜-管腔界面抽吸液,用液相色谱质谱分析18例非IBD和42例IBD患者的MLI蛋白质组,并用酶联免疫吸附试验在24份粪便样本中评估部分蛋白质标志物。
主要发现
- 四蛋白组合区分活动性IBD与非IBD(发现队列):升结肠灵敏度0.954(95%CI 0.772-0.999),降结肠灵敏度>0.999(95%CI 0.824-1.00);升结肠和降结肠特异度均>0.999(升结肠95%CI 0.815-1.00;降结肠95%CI 0.692-1.00)。
- 另一四蛋白组合区分UC患者全结肠炎与非全结肠炎:灵敏度>0.999(95%CI 0.590-1.00),特异度>0.999(95%CI 0.715-1.00)。
- IBD粪便样本中过氧化氢酶(p<0.0001)和LTA4H(p=0.0002)较非IBD粪便样本升高。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Improved biomarkers are an unmet clinical need for suspected inflammatory bowel disease (IBD). Need is greatest for children, since current biomarkers suffers from low specificity, particularly in this population; thus, invasive testing methods, with the accompanying risk of complications, are necessary. Additionally, current biomarkers do not delineate disease extent assessment for ulcerative colitis (UC), a factor involved in therapeutic decisions. METHODS: Intestinal mucosal-luminal interface (MLI) aspirates from the ascending colon (AC) and descending colon (DC) were collected during diagnostic colonoscopy from treatment-naïve children. The MLI proteomes of 18 non-IBD and 42 IBD patients were analyzed by liquid chromatography mass spectrometry. Analyses of proteomic data generated protein panels distinguishing IBD from non-IBD and pancolitis from non-pancolitis (UC disease extent). Select protein biomarkers were evaluated in stool samples by enzyme-linked immunosorbent assay (n = 24). RESULTS: A panel of four proteins discriminated active IBD from non-IBD (discovery cohort) with a sensitivity of 0.954 (95% confidence interval (CI): 0.772-0.999) and >0.999 (95% CI: 0.824-1.00) for the AC and DC, respectively, and a specificity of >0.999 (AC, 95% CI: 0.815-1.00; DC, 95% CI:0.692-1.00) for both the AC and DC. A separate panel of four proteins distinguished pancolitis from non-pancolitis in UC patients with sensitivity >0.999 (95% CI: 0.590-1.00) and specificity >0.999 (95% CI: 0.715-1.00). Catalase (p < 0.0001) and LTA4H (p = 0.0002) were elevated in IBD stool samples compared to non-IBD stool samples. CONCLUSION: This study identified panels of proteins that have significantly different expression levels and contribute to accurate IBD diagnosis and disease extent characterization in children with UC. Biomarkers identified from the MLI demonstrate transferable results in stool samples.
引用
- Deeke SA, Starr AE, Ning Z, et al. Mucosal-luminal interface proteomics reveals biomarkers of pediatric inflammatory bowel disease-associated colitis. Am J Gastroenterol. 2018. PMID: 29531307. doi:10.1038/s41395-018-0024-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。